Latest Breaking News On - Dermatology life quality index - Page 1 : comparemela.com

Upadacitinib Led to Sustained, 140-Week Improvements for Atopic Dermatitis Patients

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

Dupilumab Versus Lebrikizumab with Topical Corticosteroids: Efficacy in Atopic Dermatitis

These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.

Ruxolitinib Consistent in Safety, Tolerability Over 52-Weeks in Children with Extensive Atopic Dermatitis

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.

Study Highlights Real-World Data on Efficacy, Daily Clinical Use of Tralokinumab for Atopic Dermatitis

Study Confirms Efficacy of Guselkumab Treatment of Psoriasis After Ustekinumab Discontinuation

These multicenter, retrospective data highlight the use of guselkumab after discontinuing ustekinumab treatment up to 156 weeks of use.